FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 10/017,905	ATTY. DOCKET NO.: B0801.70238US00	
	FILING DATE: December 14, 2001	CONFIRMATION NO.: 7653	
2	APPLICANT: Paul Ridker et al.		
Sheet 1 of 1	GROUP ART UNIT: 1644	EXAMINER: G.R. Ewoldt	

ILS. PATENT DOCUMENTS

U.S. FATENT BOCOMENTS								
Examiner's Initials #	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or Issue			
	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY			

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	For Office/ Country	eign Patent Docur Number	nent Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, estalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ASAKURA, Toshio "Glycosylated Hemoglobin (HbAlc) and Diabetes Mellitus", Seitai no Kagaku, 1981, May, Vol. 32, No. 3, p. 242-249 Abstract only.	Y
		KUMON, Y. et al. "Serum Amyloid A Protein in Patients with Non-Insulin-Dependent Diabetes Mellitus", Clin. Biochem., 1994, December, Vol. 27, No. 6, p. 469-473.	
		NAKAHARA, Rieko et al. "The Significance of Blood Leptin Concentration Measurements in Type 2 Diabetes patients", Proceedings of the 47th National Congress of the Japanese Society of Laboratory Medicine, September 25, 2000, Vol. 48, Supplement, p. 241. Abstract only.	Y
		PICKUP et al., "Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes," <i>Life Sciences</i> , June 2000, Vol. 67, pgs. 291-300.	
		UCHIMURA, I. et al. "Interleukin-6 and its Hemorhelogical Effects in Diabetes Mellitus", Biorheology, 1992, Vol. 29, No. 1, p. 27.	
		VIJAN, N. et al., "Screening, Prevention, Counseling, and Treatment for the Complications of Type II Diabetes Mellitus. Putting Evidence into Practice" J Gen Intern Med, 1997, Vol. 12, pgs. 567-580.	

EXAMINER	DATE CONSIDERED	
EARMINER	DATE CONSIDERED	

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, umpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 1257GGIS. October of all other patentiel, publications(), published, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that compiles with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).